Drug Profile
Research programme: rare disease therapeutics - Takeda/Cincinnati Children's Hospital Medical Center
Alternative Names: Orphan disease therapeutics - Takeda/Cincinnati Children's Hospital Medical CenterLatest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Cincinnati Childrens Hospital Medical Center; Shire
- Developer Cincinnati Childrens Hospital Medical Center
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Unspecified in USA
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 17 Apr 2015 Early research in rare disease indications in USA (unspecified route)